A mapping of drug space from the viewpoint of small molecule metabolism

PLoS Computational Biology

Volumn 5, Issue 8, 2009, Pages

  Adams, James Corey ^a   Keiser, Michael J ^a   Basuino, Li ^a   Chambers, Henry F ^a   Lee, Deok Sun ^b,c,d   Wiest, Olaf G ^e   Babbitt, Patricia C ^a,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTHEASTERN UNIVERSITY   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d Inha University   (South Korea)

^e UNIVERSITY OF NOTRE DAME   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYMES; FORECASTING; LIGANDS; MAPPING; METABOLITES; MOLECULES; PHYSIOLOGY;

CHEMICAL SPACE; DEGREE OF SIMILARITY; DRUG DISCOVERY; DRUG TARGETS; LARGE-SCALES; MANY-CORE; METABOLIC ENZYMES; ONLINE RESOURCES; SMALL MOLECULES; SMALL-MOLECULE DRUGS;

METABOLISM;

DRUG METABOLITE; DRUG METABOLIZING ENZYME; FOLIC ACID; PYRIMIDINE; DRUG; ENZYME;

ARTICLE; CHEMICAL REACTION; DRUG METABOLISM; DRUG TARGETING; HUMAN; NONHUMAN; POLYPHARMACY; PYRIMIDINE SYNTHESIS; ANIMAL; BIOLOGY; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; ENZYMOLOGY; FACTUAL DATABASE; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHODOLOGY; PHYSIOLOGY;

ANIMALS; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; ENZYMES; HUMANS; METABOLIC NETWORKS AND PATHWAYS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PHARMACEUTICAL PREPARATIONS;

EID: 70049097554     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1000474     Document Type: Article

References (59)

1. Johnson M, Lajiness M, Maggiora G (1989) Molecular similarity: a basis for designing drug screening programs. Prog Clin Biol Res 291: 167-171.
2. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29-40.
3. Kramer JA, Sagartz JE, Morris DL (2007) The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov 6: 636-649.
4. Drews J (2006) Case histories, magic bullets and the state of drug discovery. Nat Rev Drug Discov 5: 635-640.
5. Paolini GV, Shapland RH, van Hoorn WP, Mason JS, Hopkins AL (2006) Global mapping of pharmacological space. Nat Biotechnol 24: 805-815.
6. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, et al. (2007) Relating protein pharmacology by ligand chemistry. Nat Biotechnol 25: 197-206. (Pubitemid 46227119)
7. Cleves AE, Jain AN (2006) Robust ligand-based modeling of the biological targets of known drugs. J Med Chem 49: 2921-2938.
8. Watkins SM, German JB (2002) Metabolomics and biochemical profiling in drug discovery and development. Curr Opin Mol Ther 4: 224-228. (Pubitemid 35282867)
9. Shyur LF, Yang NS (2008) Metabolomics for phytomedicine research and drug development. Curr Opin Chem Biol 12: 66-71.
10. Rochfort S (2005) Metabolomics reviewed: a new "omics" platform technology for systems biology and implications for natural products research. J Nat Prod 68: 1813-1820.
11. Kell DB (2006) Systems biology, metabolic modelling and metabolomics in drug discovery and development. Drug Discov Today 11: 1085-1092. (Pubitemid 44810914)
12. Caspi R, Foerster H, Fulcher CA, Kaipa P, Krummenacker M, et al. (2008) The MetaCyc Database of metabolic pathways and enzymes and the BioCyc collection of Pathway/Genome Databases. Nucleic Acids Res 36: D623-631. (Pubitemid 351149796)
13. Dobson CM (2004) Chemical space and biology. Nature 432: 824-828.
14. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M (2007) Drug-target network. Nat Biotechnol 25: 1119-1126.
15. Yamanishi Y, Araki M, Gutteridge A, Honda W, Kanehisa M (2008) Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 24: i232-240. (Pubitemid 351911678)
16. Cheng AC, Coleman RG, Smyth KT, Cao Q, Soulard P, et al. (2007) Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol 25: 71-75. (Pubitemid 46087905)
17. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, et al. (2007) The human disease network. Proc Natl Acad Sci U S A 104: 8685-8690.
18. Hajduk PJ, Huth JR, Tse C (2005) Predicting protein druggability. Drug Discov Today 10: 1675-1682.
19. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1: 727-730.
20. Imming P, Sinning C, Meyer A (2006) Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 5: 821-834. (Pubitemid 44480536)
21. Meisner NC, Hintersteiner M, Uhl V, Weidemann T, Schmied M, et al. (2004) The chemical hunt for the identification of drugable targets. Curr Opin Chem Biol 8: 424-431. (Pubitemid 38993736)
22. Russ AP, Lampel S (2005) The druggable genome: an update. Drug Discov Today 10: 1607-1610.
23. Lee DS, Park J, Kay KA, Christakis NA, Oltvai ZN, et al. (2008) The implications of human metabolic network topology for disease comorbidity. Proc Natl Acad Sci U S A 105: 9880-9885.
24. Navarro MB, Huttner B, Harbarth S (2008) Methicillin-resistant Staphylococcus aureus control in the 21st century: beyond the acute care hospital. Curr Opin Infect Dis 21: 372-379.
25. Powell JP, Wenzel RP (2008) Antibiotic options for treating community-acquired MRSA. Expert Rev Anti Infect Ther 6: 299-307.
26. Clements A, Halton K, Graves N, Pettitt A, Morton A, et al. (2008) Overcrowding and understaffing in modern health-care systems: key determinants in meticillin-resistant Staphylococcus aureus transmission. Lancet Infect Dis 8: 427-434. (Pubitemid 351863737)
27. Avdic E, Cosgrove SE (2008) Management and control strategies for community-associated methicillin-resistant Staphylococcus aureus. Expert Opin Pharmacother 9: 1463-1479. (Pubitemid 352011825)
28. Nicasio AM, Kuti JL, Nicolau DP (2008) The current state of multidrug-resistant gram-negative bacilli in North America. Pharmacotherapy 28: 235-249.
29. James C, Weininger D, Delaney J (1992-2005) Daylight Theory Manual. Mission Viejo, CA: Daylight Chemical Information Systems Inc.
30. MDL Information Systems I (2006) MDL Drug Data Report. San Leandro, CA: MDL Information Systems, Inc.
31. Tipton KF (1992) Enzyme Nomenclature: Recommendations of the Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (IUBMB). New York: NC-IUBMB.
32. Schuffenhauer A, Zimmermann J, Stoop R, van der Vyver JJ, Lecchini S, et al. (2002) An ontology for pharmaceutical ligands and its application for in silico screening and library design. J Chem Inf Comput Sci 42: 947-955. (Pubitemid 35355244)
33. Ciruela F, Saura C, Canela EI, Mallol J, Lluis C, et al. (1996) Adenosine deaminase affects ligand-induced signalling by interacting with cell surface adenosine receptors. FEBS Lett 380: 219-223. (Pubitemid 26063938)
34. Mackay K, Starr JR, Lawn RM, Ellsworth JL (1997) Phosphatidylcholine hydrolysis is required for pancreatic cholesterol esterase- and phospholipase A2-facilitated cholesterol uptake into intestinal Caco-2 cells. J Biol Chem 272: 13380-13389. (Pubitemid 27216771)
35. Romero P, Wagg J, Green ML, Kaiser D, Krummenacker M, et al. (2005) Computational prediction of human metabolic pathways from the complete human genome. Genome Biol 6: R2.
36. Martin R, Rose D, Yu K, Barros S (2006) Toxicogenomics strategies for predicting drug toxicity. Pharmacogenomics 7: 1003-1016. (Pubitemid 44644780)
37. Ekins S, Andreyev S, Ryabov A, Kirillov E, Rakhmatulin EA, et al. (2005) Computational prediction of human drug metabolism. Expert Opin Drug Metab Toxicol 1: 303-324.
38. Lewis W (2004) Cardiomyopathy, nucleoside reverse transcriptase inhibitors and mitochondria are linked through AIDS and its therapy. Mitochondrion 4: 141-152.
39. Petit F, Fromenty B, Owen A, Estaquier J (2005) Mitochondria are sensors for HIV drugs. Trends Pharmacol Sci 26: 258-264. (Pubitemid 40603074)
40. Lewis W, Kohler JJ, Hosseini SH, Haase CP, Copeland WC, et al. (2006) Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis. Aids 20: 675-684. (Pubitemid 43884294)
41. Kisliuk RL (2000) Synergistic interactions among antifolates. Pharmacol Ther 85: 183-190.
42. Faessel HM, Slocum HK, Rustum YM, Greco WR (1999) Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H- pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG2034): comparison across sensitive and resistant human tumor cell lines. Biochem Pharmacol 57: 567-577.
43. Chan DC, Anderson AC (2006) Towards species-specific antifolates. Curr Med Chem 13: 377-398.
44. Costi MP, Ferrari S, Venturelli A, Calo S, Tondi D, et al. (2005) Thymidylate synthase structure, function and implication in drug discovery. Curr Med Chem 12: 2241-2258. (Pubitemid 41179710)
45. Gmeiner WH (2005) Novel chemical strategies for thymidylate synthase inhibition. Curr Med Chem 12: 191-202.
46. McGuire JJ (2003) Anticancer antifolates: current status and future directions. Curr Pharm Des 9: 2593-2613. (Pubitemid 37456011)
47. Chu E, Callender MA, Farrell MP, Schmitz JC (2003) Thymidylate synthase inhibitors as anticancer agents: from bench to bedside. Cancer Chemother Pharmacol 52 Suppl 1: S80-89. (Pubitemid 37047028)
48. Lee DS, Burd H, Liu J, Almaas E, Wiest O, et al. (2009) Comparative genome-scale metabolic reconstruction and flux balance analysis of multiple Staphylococcus aureus genomes identify novel antimicrobial drug targets. J Bacteriol 191: 4015-4024.
49. Dias MV, Ely F, Palma MS, de Azevedo WF Jr, Basso LA, et al. (2007) Chorismate synthase: an attractive target for drug development against orphan diseases. Curr Drug Targets 8: 437-444. (Pubitemid 46381294)
50. Cho Y, Ioerger TR, Sacchettini JC (2008) Discovery of novel nitrobenzothiazole inhibitors for Mycobacterium tuberculosis ATP phosphoribosyl transferase (HisG) through virtual screening. J Med Chem 51: 5984-5992.
51. Zhang C, Crasta O, Cammer S, Will R, Kenyon R, et al. (2008) An emerging cyberinfrastructure for biodefense pathogen and pathogen-host data. Nucleic Acids Res 36: D884-891. (Pubitemid 351149840)
52. Bogoyevitch MA, Fairlie DP (2007) A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding. Drug Discov Today 12: 622-633.
53. Ciulli A, Abell C (2007) Fragment-based approaches to enzyme inhibition. Curr Opin Biotechnol 18: 489-496.
54. Moore EC, Hurlbert RB, Boss GR, Massia SP (1989) Inhibition of two enzymes in de novo purine nucleotide synthesis by triciribine phosphate (TCN-P). Biochem Pharmacol 38: 4045-4051.
55. Tondi D, Slomczynska U, Costi MP, Watterson DM, Ghelli S, et al. (1999) Structure-based discovery and in-parallel optimization of novel competitive inhibitors of thymidylate synthase. Chem Biol 6: 319-331. (Pubitemid 29363182)
56. Hert J, Willett P, Wilton DJ, Acklin P, Azzaoui K, et al. (2004) Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures. Org Biomol Chem 2: 3256-3266.
57. Willett P (2006) Similarity-based virtual screening using 2D fingerprints. Drug Discov Today 11: 1046-1053. (Pubitemid 44792477)
58. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. Jour Mol Biol 215: 403-410. (Pubitemid 20364473)
59. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504. (Pubitemid 37428274)